High strength, low modulus, ductile, biopcompatible titanium alloy

• US 4,857,269 A
• Filed: 09/09/1988
• Issued: 08/15/1989
• Est. Priority Date: 09/09/1988
• Status: Expired due to Term

• Current Assignee: Howmedica Osteonics Corp. (Stryker Corporation)
• Original Assignee: Pfizer Hospital Products Group, Inc. (Pfizer Inc.)
• Inventors: Dumbleton, John H., Wang, Kathy K., Gustavson, Larry J.
• Primary Examiner(s): Roy, Upendra
• Application Number:
  US07/242,750
• Time in Patent Office: 340 Days
• Field of Search: 128/593, 623/16, 623/23, 420/417, 420/418, 420/421, 148/11.5 F, 148/133
• US Class Current: 420/417
• CPC Class Codes: A61F 2310/00023 Titanium or titanium-based alloys, e.g. Ti-Ni alloys
• CPC Class Codes: A61L 27/06 Titanium or titanium alloys
• CPC Class Codes: C22C 14/00 Alloys based on titanium

Abstract

A high strength, low modulus, ductile, biocompatible titanium base alloy containing one or more isomorphous beta stabilizers, eutectoid beta stabilizers and optional alpha stabilizers, characterized by a modulus of elasticity not exceeding 100 GPa; a method for the preparation of said alloy and prostheses made from said alloy.

Claims

1. A high strength, low modulus, ductile, biocompatible titanium base alloy consisting essentially of the following alloying components:

an amount up to 24% by weight of at least one isomorphous beta stabilizer selected from the group consisting of molybdenum, tantalum, niobium and zirconium, provided that molybdenum, when present, is in an amount of at least 10% by weight, and when molybdenum is present with zirconium the molybdenum is in an amount of 10 to 13% by weight and the zirconium is in an amount of 5 to 7% by weight;

an amount up to 3.0% by weight of at least one eutectoid beta stabilizer selected from the group consisting of iron, manganese, chromium, cobalt and nickel Wherein the combined amount of isomorphous beta stabilizer and eutectoid beta stabilizer is at lest 10.2 percent by weight;

optionally an amount up to 3.0% by weight of at least one metallic alpha stabilizer selected from the group consisting of aluminum and lanthanum;

and the balance titanium, apart from incidental impurities, but not exceeding by weight, among the non-metallic alpha stabilizers, 0.05% carbon, 0.30% oxygen and 0.02% nitrogen; and

not exceeding 0.02% of the eutectoid former hydrogen;

the proportion of each of the alloying components being balanced to provide an alloy having a modulus of elasticity not exceeding 100 GPa.

2. An alloy according to claim 1, having a modulus of elasticity of 66.9 to GPa;

a 0.2% offset yield strength of 925 to 1221 MPa;

a rotating beam fatigue strength of 483 to 621 MPa at 10⁷ cycles and of 345 to 380 MPa at a stress concentration factor, K_t, of 1.6; and

a tensile elongation of at least 10%.

3. An alloy according to claim 1, consisting essentially of 10 to 13% by weight of molybdenum;

5 to 7% by weight of zirconium;

0.2 to 3.0% by weight of iron;

0 to 3.0% by weight of aluminum; and

the balance titanium, apart from incidental impurities.

4. An alloy according to claim 1, consisting essentially of 10.0 to 20.0% by weight niobium;

1.0 to 4.0% by weight zirconium;

about 2.0% by weight iron;

up to 1.0% by weight aluminum; and

the balance titanium, apart from incidental impurities.

5. A prosthesis made from a high strength, low modulus, ductile, biocompatible titanium base alloy according to claim 1.

6. An alloy according to claim 3 consisting essentially of about 11.5% by weight molybdenum, about 6.0% by weight zirconium;

about 0.4 to about 2.0% by weight iron, 0 to about 1.0% by weight aluminum; and

the balance titanium, apart from incidental impurities.